The implantable cardiac monitor (ICM) market is expanding rapidly as the demand for continuous heart monitoring increases, especially for managing conditions like arrhythmias and atrial fibrillation.
The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure (AHF) and early cardiogenic shock (ECS), including the latest ...